[go: up one dir, main page]

EP1490112A1 - Procede et agent de fabrication de compositions sanguines therapeutiquement actives - Google Patents

Procede et agent de fabrication de compositions sanguines therapeutiquement actives

Info

Publication number
EP1490112A1
EP1490112A1 EP03727267A EP03727267A EP1490112A1 EP 1490112 A1 EP1490112 A1 EP 1490112A1 EP 03727267 A EP03727267 A EP 03727267A EP 03727267 A EP03727267 A EP 03727267A EP 1490112 A1 EP1490112 A1 EP 1490112A1
Authority
EP
European Patent Office
Prior art keywords
blood
cells
nucleic acid
transformed
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03727267A
Other languages
German (de)
English (en)
Inventor
Hans Meijer
Julio Reinecke
Peter Wehling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orthogen AG
Original Assignee
Orthogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthogen AG filed Critical Orthogen AG
Publication of EP1490112A1 publication Critical patent/EP1490112A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the invention essentially relates to methods for producing induced blood compositions from blood, the blood cells transiently or stably expressing and possibly secreting one or more therapeutically or diagnostically important proteins and / or effector molecules.
  • Recombinant proteins produced in a conventional manner can lead to intolerance reactions, in particular due to the impurities contained in the protein preparations themselves and through possible reactions of the organism, in particular immune reactions, to the proteins and / or the Impurities.
  • the aim is therefore to provide recombinant proteins obtained from, in particular autologous, cells of the animal or human body, which are also readily available.
  • Van Tendeloo et al. (Gene Therapy (2000) 7: 1431-1437) describe systems for gene transfer into primary human blood cells by means of electroporation, wherein human T-lymphocytes and / or adult bone marrow cells of the CD34 + type are activated as blood cells in their cultured form can be transfected by electroporation.
  • the T-lymphocytes are activated by the use of PHA or by CD3 “cross linking” and by interleukin-2 before the transfection.
  • the technical problem on which the present invention is based is that Development of methods and means for their implementation, which make it possible to obtain eukaryotic, therapeutically and / or diagnostically important proteins, in particular autologous proteins, from blood cells, in particular autologous blood cells.
  • the technical problem is essentially solved by a transient, genetic transformation of blood cells, the preferably subsequent cultivation of these cells in the serum and the preferred subsequent application of the protein produced in the serum, in particular without purification:
  • the problem is solved by a method for producing a Induced blood composition dissolved from blood, wherein blood cells containing blood, in particular in whole blood, that is to say in the unpurified and / or fractionated blood, are transient, that is to say limited for a certain period of time, or stable, that is to say permanently, with at least one nucleic acid molecule , in particular DNA or RNA, are transformed.
  • the at least one nucleic acid molecule preferably encodes at least one gene product, preferably a protein, particularly preferably a therapeutically and / or diagnostically important protein and / or at least one effector molecule, for example an effector protein, or preferably at least one nucleic acid molecule, in particular RNA, which is the therapeutic or serum concentration diagnostically relevant proteins modulated, preferably increased.
  • an induced blood composition which comprises at least one transformed blood cell which transiently or stably expresses the at least one gene product, in particular a therapeutically and / or diagnostically important protein and / or effector molecule, and this preferably optionally releases, that is, secretes, and, in particular in a further step, the at least one gene product, preferably the therapeutically and / or diagnostically important protein and / or effector molecule and / or at least one effector molecule-regulated therapeutically and / or from the induced blood composition or diagnostically important protein is obtained.
  • the use of blood as a raw material on the one hand and as a production system for the at least one gene product on the other hand, preferably together with an application of the at least one preferably produced protein, is particularly simple and inexpensive, particularly in serum. It also shows that the eukaryotic blood cells process the proteins correctly. In addition, particularly advantageously, no contaminants or other immunogenic components occur in the production system according to the invention, which is preferably autologous or heterologous, which could lead to intolerance reactions in a recipient of the gene product.
  • the blood composition When using an effector molecule obtained according to the invention, that is to say a gene product which in particular modulates, preferably increases, the serum concentration of therapeutically and / or diagnostically important proteins, the blood composition particularly advantageously contains only autologous, that is to say from the donor, and therapeutically and / or diagnostically important proteins. An immunological reaction upon application, preferably re-application, of the blood composition thus produced can therefore be practically ruled out.
  • effector molecule in particular effector protein, coding nucleic acid molecule or effector molecule, which stimulates the production of a large number, preferably any, of proteins
  • the proteins are produced and / or released in a natural quantitative relationship to one another.
  • effector molecules are transcription factors, proteins which are part of the signal transduction chain, extracellular signal molecules such as cytokines or anti-sense RNAs.
  • the blood composition induced according to the invention has at least one therapeutically and / or diagnostically important protein in a higher concentration than an untransformed blood composition.
  • therapeutically and / or diagnostically important proteins such as cytokines, such as the natural or modified interleukin-1 receptor antagonist, IL-1 Ra, (IRAP) are preferred.
  • At least one effector molecule, in particular effector protein is preferably expressed in at least one blood cell of the blood composition induced according to the invention, which is not expressed at all in non-transformed blood cells or in an amount which is less than the amount which of the at least one, the effector molecule, in particular Effector protein, expressing blood cell of the blood composition induced according to the invention is produced.
  • the blood for producing the induced blood composition is taken from an organism, in particular a human or animal body, patients or test subjects with at least one withdrawal system, preferably a syringe.
  • the blood is preferably transformed with the at least one nucleic acid molecule within the syringe, the blood cells to be transformed not being separated beforehand from other blood components of the blood drawn, that is to say fractionated.
  • the blood is withdrawn with at least one withdrawal system, preferably with a syringe, and then filled into at least one further vessel.
  • the blood withdrawn is preferably transformed in this at least one further vessel, preferably without first separating the blood cells to be transformed from other blood components, ie as non-fractionated blood, in particular as whole blood.
  • blood cells in particular nuclear cells such as mononuclear cells, PBMC, are separated from other blood components from the blood drawn, and the blood cells are transformed and stored in medical to with or without serum, in particular autologous serum, preferably autologous serum, which was obtained as an isolated blood component in the above-mentioned separation, ie fractionation, or in pure, that is to say undiluted, serum, in particular pure, autologous serum, preferably pure , autologous serum, which was obtained as an isolated blood component in the above-mentioned separation.
  • autologous serum preferably autologous serum
  • the at least one nucleic acid molecule to be transformed is preferably contained in a vector, for example in a plasmid or in a virus.
  • the at least one nucleic acid molecule to be transformed is preferably functionally linked to at least one regulatory element, for example a promoter, enhancer or intron, in particular at least one blood cell-specific regulatory element.
  • the at least one nucleic acid molecule to be transformed is functionally linked to at least one nucleotide section encoding a signal peptide for protein secretion from the cell.
  • the nucleic acid molecule to be transformed in particular DNA or RNA, is preferably labeled with at least one marker substance.
  • this marker substance is used to remove excess, that is to say untransformed, DNA after the transformation process has been completed.
  • the nucleic acid molecule to be transformed in particular DNA or RNA, is preferred together with at least at least one further substance, which modulates, preferably increases, the transfection rate and / or the expression rate of the nucleic acid molecule to be transformed.
  • the further substance preferably fulfills at least one of the following functions: a) recognition of the surfaces of specific cell types in order to specifically transform these cells, b) increasing the absorption efficiency of the nucleic acid molecule to be transformed into the cell, c) optimization of the nuclear transport of the nucleic acid molecule to be transformed, d) increasing the transcription efficiency of the transgene in the transformed cell.
  • the at least one nucleic acid molecule to be transformed in particular DNA or RNA
  • Transfection with spheres, preferably micro-glass spheres is a system in which spheres, preferably glass spheres, are coated (“coated”) with nucleic acid molecules, preferably with plasmid DNA.
  • “micro-glass spheres” or “glass spheres” are not only understood to mean glass spheres made of glass, but also spheres made of other materials which are comparable in function to glass, in particular nucleic acid molecules that are covalent and / or non-covalent - You can, for example polymeric plastics such as polyethylene, polypropylene, polystyrene, polytetrafluoroethylene, polyacrylates, polyamides, polycarbonates, polyimides, polyacetates, polyolefins, silicones, polysilanes, latex and the like and / or mixtures thereof.
  • the balls are preferably also designed as magnetic balls.
  • the size of the balls or granulate particles is preferably between 2 and 4 mm
  • nucleic acid molecules in particular DNA or RNA, preferably plasmid DNA, are taken up in the cells, reach the cell nucleus and are expressed there.
  • nucleic acid molecules on a solid support for example on the large or small glass spheres and / or on the surface of the sampling system, preferably in the form of a syringe, and / or on other vessels containing blood or separated blood fractions To be brought in contact. Nucleated blood cells from the blood drawn adhere specifically to this carrier, as in the case of larger spheres, and / or phagocytize this carrier, as in the case of smaller spheres.
  • the balls are coated with the nucleic acid molecules preferably in a covalent or non-covalent manner.
  • a covalent, especially an acid-labile covalent, bond is particularly effective when the carrier is broken up by phagocytosis. be taken.
  • Non-covalent binding is particularly effective if the DNA is taken up after adherence.
  • Electroporation is provided as an alternative and / or additional transformation method.
  • the at least one nucleic acid molecule to be transformed in particular DNA or RNA, is therefore transformed by electroporation of the blood cells to be transformed.
  • the nucleic acid molecule to be transformed contains at least one nucleic acid molecule which induces, represses and / or regulates the expression of the body's own proteins, for example at least one antisense construct, RNA element, transposable element, transcription factor, in particular it consists of this.
  • the ex- Pression of the at least one transgenic gene product in particular the therapeutically and / or diagnostically important protein and / or effector in the at least one transgenic blood cell and the secretion from the blood cell into the serum, the at least one blood cell and optionally at least one further non-transformed blood cell from the induced blood composition separated from the serum and an induced, preferably cell-free, serum obtained.
  • the nucleic acid molecule to be transformed is particularly preferably transformed with the aid of liposomes, viral vectors or bound to large and / or small spheres, in particular microglass spheres, in particular if appropriate the at least one nucleic acid molecule to be transformed being acid-labile to the large and / or small spheres is bound.
  • the present invention also relates to a method for transforming at least one cell, in particular in the blood, for example blood cells, with at least one nucleic acid molecule, the cell and / or blood cells being brought into contact with the nucleic acid molecules, the cells and / or the blood cells present in the blood are transformed and cells or / and blood cells transformed in a stable or transient manner are obtained.
  • the nucleic acid molecules to be transformed are preferably bound, in particular covalently, in particular acid-labile, to large and / or small balls, in particular microglass balls, before the transformation.
  • Another object of the invention is a method for treating the human or animal body, wherein the human or animal body blood, preferably by means of at least one syringe, and an aforementioned method according to the invention is carried out, in particular to produce an induced blood composition.
  • the induced blood composition is re-applied to, preferably the same, human or animal body, preferably reapplied.
  • the induced blood serum is applied to the human or animal body.
  • the induced blood composition or the induced blood serum is not re-applied in the same animal or human body, but rather is applied in another animal or human body.
  • Another object of the invention is the use of large and / or small spheres such as microglass beads, to which nucleic acid molecules are bound, preferably covalently, preferably acid-labile, for the transformation of blood, preferably of nuclear cells from blood, in particular in whole blood.
  • nucleic acid molecules preferably of nuclear cells from blood, in particular in whole blood.
  • preference is given to the use for the expression and secretion of proteins and / or effectors in the blood, in particular in blood cells.
  • Another object of the invention is therefore also the use for the transformation of biological cells, in particular eukaryotic cells, particularly preferably plant, fungal or animal cells such as mammalian cells, in particular human cells.
  • another subject of the invention is the use of blood, in particular whole blood, for the transformation of nucleic acid molecules encoding at least one therapeutically and / or diagnostically important protein and / or effector molecule, into at least one blood cell of the blood, in particular whole blood, for therapeutic, in particular gene therapy Purposes, preferably for gene therapy and / or the treatment of leukemia, the treatment of traumatic, degenerative, chronic inflammatory diseases of the nervous system, the musculoskeletal system or various internal organs.
  • Another object of the invention is therefore the use of blood, in particular whole blood, for the production of pharmaceutical kits, in particular from an induced blood composition and / or induced serum produced according to the invention, for the aforementioned therapeutic purposes.
  • Another object of the invention is also the use of nucleotide molecules, in particular coding for at least one therapeutically and / or diagnostically important protein and / or effector molecule, for the transformation of blood, in particular of at least one blood cell contained in the blood, and the expression and, if appropriate, secretion at least one therapeutically and / or diagnostically important protein and / or effector molecule for the aforementioned therapeutic purposes.
  • Another object of the invention is the use of these nucleotide molecules, in particular coding for therapeutically and / or diagnostically important proteins and / or effector molecules, for the production of a pharmaceutical kit for this transformation.
  • the pharmaceutical production of the at least one, in particular therapeutically and / or diagnostically significant, preferably autologous protein preferably takes place by the patient's own blood cells and the subsequent autologous therapeutic application.
  • the processing and application of the serum are provided.
  • PBMCs peripheral blood mononuclear cells
  • the transformation is preferably carried out a) without growth induction with, for example, mitogenic or growth-stimulating substances such as interleukin-2 (IL-2) or b) with growth induction with, for example, mitogenic or growth-stimulating substances such as IL-2.
  • mitogenic or growth-stimulating substances such as interleukin-2 (IL-2)
  • IL-2 interleukin-2
  • the cells are grown further without or with further growth induction. It has been shown that, in particular, the use of electrical fields, in particular in electroporation, stimulates cell growth and / or cell development. Electrostimulation is therefore also intended as an alternative to known growth-stimulating substances.
  • the nucleic acid molecules to be transformed are coupled to a support, the serum being centrifuged after the incubation, and the serum which contains the desired proteins removed and filtered after the centrifugation is used to remove the last carrier and cell residues, the untransformed nucleic acid molecules being removed together with the carriers.
  • labeled nucleic acid molecules are used, additives, in particular carriers, which have an affinity for the labeled nucleic acid molecules being added to the serum after the incubation.
  • nucleic acid molecules preferably labeled with biotin carriers coated with streptavidin are used which bind the biotin-labeled molecules.
  • the carriers are then removed from the serum by means of centrifugation and / or, in the case of magnetic carriers, by means of magnetism, the non-transformed nucleic acid molecules bound to the carrier being removed from the serum.
  • the serum with the untransformed nucleic acid molecules contained therein is purified by means of at least one filter which has an affinity for the nucleic acid molecules.
  • nucleic acid molecules labeled with biotin bind to a filter coated with streptavidin.
  • both cell residues and excess, non-transformed nucleic acid molecules are particularly advantageously removed from the serum in a single step.
  • FIG. 1 shows the IL-1 ⁇ content in the blood cell culture after the pyrogenicity test of the plasmid pcDNA-IL-1Ra
  • FIG. 2 shows the dependence of the DNA binding on glass spheres on the pH of the buffer
  • FIG. 3 shows the dependence of the DNA binding on glass balls on the incubation time in DNA-containing buffer
  • FIG. 4 an agarose gel (2%) after PCR on a dilution series of pcDNA-IL-1 Ra in TE and on ball wash water, ethidium bromide staining.
  • the arrows show the comparable dilution levels
  • FIG. 5 an agarose gel (2%) after the PCR on a dilution series of pcDNA-IL-1 Ra in human serum, ethidium bromide staining, the control contains no “template” DNA (“water control”),
  • FIG. 6 an agarose gel (2%) after a “nested” PCR on a dilution series of pcDNA IL-1Ra in human serum, ethidium bromide staining, the control contains no “template” DNA (“water control”),
  • FIG. 7 an agarose gel (2%) after PCR on a dilution series of pcDNA-IL-1Ra in human serum, sample material of the syringe system according to the invention with “bead transfection” and the ORTHOKIN® system, staining using ethidium bromide
  • FIG. 8 shows the IL-1 Ra content after “bead transfection” in the blood cell culture
  • FIG. 9 shows the IL-1Ra content in the serum supernatant after 24 hours of incubation of whole blood, comparison of the syringe system according to the invention with “bead transfection” with the ORTHOKIN® system, a perfusor syringe without balls and with the zero sample,
  • FIG. 10 shows a representation of the specific activity of the ⁇ -galactosidase after electroporation of PBMCs with pVaxLacZ
  • FIG 11 - a schematic representation of a syringe (1) according to the invention made of glass or plastic with a plunger (3), an optionally screwable closure (5), a closure attachment (13) and a removable cap (7) arranged thereon and closing it septum.
  • the stamp (3) preferably has a predetermined breaking point (15).
  • Granulate (9) coated according to the invention is also shown in the lumen of the syringe.
  • Example 1 Transformation of a blood cell culture with the aid of DNA-coated microglass beads (“bead transfection”).
  • Blood cell culture is a system that is mainly used in research and development.
  • the blood cell culture is used to cultivate whole blood. This method is used for "bead transfection” and for the toxicity test of DNA.
  • a 48-well cell culture plate (Nunc, Wiesbaden) is prepared according to the experimental approach by introducing microglass beads for "bead transfection” or DNA for a toxicity test.
  • non-coagulated whole blood is added to the wells, whereby approximately 1 ml per cavity are used for a 48-well plate, and part of the whole blood is centrifuged as a zero sample for about 5 minutes at 5000 xg, after which the supernatant is removed and placed in a cavity of a 96-well plate.
  • the plate with the zero sample is closed and stored frozen at -80 ° C.
  • the 48-well cell culture plate is also closed and incubated for about 24 hours at about 37 ° C. with 5% CO 2 saturation and saturated air humidity. After the incubation, the serum supernatant of the samples in the 48-well cell culture plate is removed and likewise placed in the 96-well plate stored frozen at -80 ° C until analysis.
  • the interleukin-1ß content is determined in a toxicity test or pyrogenicity test; in the transfection experiments, the content of an expressed reporter or target protein is determined.
  • the volumes are adjusted accordingly.
  • the plasmid pcDNA-IL-1Ra contains at least one sequence which codes for a protein (“coding region”) and a control unit (“promoter”) which is active in eukaryotic cells. It consists of the coding region, the IL-1 Ra cDNA, in a pcDNA-1 vector (company Invitrogen, Düsseldorf). Plasmid DNA is isolated from bacterial suspensions using a commercially available system (Qiagen Maxiprep TM endofree-Kit TM, from Qiagen) according to the manufacturer's protocol. All checks suggested by the manufacturer are carried out. The quality control of the isolated plasmid is carried out in a manner known per se by means of specific PCR, restriction digestion and toxicity test or pyrogenicity test in a blood cell culture.
  • the DNA used must be non-pyrogenic.
  • the IL-1 ⁇ content was 2500 pg / ml on average.
  • DNA is not considered to be pyrogenic or endotoxin-free if the IL-1ß content after incubation with the potential pyrogen is the lowest standard of the IL-1ß-ELISA test, namely 15.2 pg / ml. does not exceed.
  • the results of the pyrogenicity test are shown in FIG. 1:
  • IL-1ß concentrations of the serum supernatant of the dilution series of pcDNA-IL-1 Ra incubated in the blood cell culture are less than 15.2 pg / ml, the DNA is not pyrogenic.
  • Plasmid DNA is bound to the surface of glass spheres under specific pH and salt conditions. Not all types of glass and
  • the balls are washed several times in succession by filling them into a 50 ml tube and this with phosphate buffer with pH 5.5 (1/15 mol / l KH 2 P0 3 , 1/15 mol / l Na 2 HP0 3 ) is replenished.
  • the balls are washed by inverting them several times; the liquid is then poured off again.
  • the washing times are between 2 minutes and 1 hour, preferably 30 minutes, per wash cycle.
  • the treatment times with acid and / or alkali are between 2 minutes and 1 hour, preferably 30 minutes.
  • this acid or alkali treatment modifies the glass surface.
  • This pretreatment or modification takes place through the use of conventional organic and / or inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, citric acid or acetic acid, etc.
  • chromium-sulfuric acid preferably 50% chromium-sulfuric acid (e.g. Merck, Darmstadt, order no . 1.02499.2500, Chromosulphuric acid is diluted with Biochrom Ultra Pure Water No. L 0040 to the desired dilution), or alkalis such as sodium hydroxide solution, potassium hydroxide solution, ammonia, etc.
  • chromium-sulfuric acid preferably 50% chromium-sulfuric acid (e.g. Merck, Darmstadt, order no . 1.02499.2500, Chromosulphuric acid is diluted with Biochrom Ultra Pure Water No. L 0040 to the desired dilution), or alkalis such as sodium hydroxide solution, potassium hydroxide solution, ammonia, etc.
  • the degree of contamination is determined by photometric measurement of the optical density (OD) at one or more wavelengths between 200 and 800, preferably at 280 nm (OD 2 see above).
  • the OD 2 usually remains so constant (see Table 1), which shows that removable dirt particles have been removed from the glass balls.
  • the balls are additionally washed with pure water, conductivity up to a maximum of about 1 ⁇ S, until the conductivity of the wash water again corresponds to the original conductivity. Then the washing step is repeated again.
  • a physiological solution such as PBS is ideally used as the binding buffer, because then the ionic strength and composition of the buffer should not be adapted for cell physiological or clinical use.
  • a pH gradient is created with PBS in the pH range from 5 to 7 and the binding of the DNA to the glass balls is tested.
  • the balls are washed between 1 and 10 times, preferably 4 times, with the respective buffer and incubated with pcDNA-IL-1Ra (10 ⁇ g / ml PBS) for 90 min. Before and after the individual steps, the purity of the spheres and the binding of the DNA are checked by means of OD measurement at 260 and 280 nm.
  • Table 1 shows typical results of an OD measurement after 4 washing steps to remove dirt particles from the glass balls.
  • the spheres are washed four times with PBS (pH as indicated in the table) in order to saturate the spheres with the ions from the buffer and then with DNA-containing buffer for different Incubated time periods (30, 60, 90, 120, 150 and 180 min). Before and after the individual steps, an OD measurement at 260 and 280 nm is used to check whether all the dust particles have been removed and then how much DNA remains.
  • the pH of the buffer, at which the largest amount of DNA binds to the spheres, is 5.5 (see FIG. 2).
  • the incubation time at which the largest amount of DNA remains adhering is 1.5 hours (see FIG. 3).
  • Table 2 shows the results of the OD measurement for checking the washing steps and determining the DNA content in samples from the ball coating.
  • the glass spheres for the further studies are filled in 50 ml sterile tubes up to 15 ml (approx. 400 spheres) and washed 4 times in PBS with a pH value of 5.5, thorough mixing being carried out during the individual washing steps.
  • the wash water is checked for dirt particles by means of OD measurement at 280 nm.
  • phosphate buffer with a pH of 5.5 (1/15 mol / l KH 2 P0 3 , 1/15 mol / l Na 2 HP0 3 ) is mixed with plasmid DNA (15 ⁇ g / ml) and 10 ml of this Put solution on the washed balls. After 1.5 hours of incubation, the DNA solution is removed and the remaining amount of DNA is determined by OD measurement.
  • the balls are washed repeatedly with PBS (pH 5.5) to remove unbound DNA.
  • Sterilization should not damage DNA and binding. Therefore, steam sterilization (leads to denaturation of the DNA) or radiation (induces mutations in the DNA) is not used.
  • the DNA-coated spheres are sterilized by adding 40 ml of 70% ethanol under the sterile bench. After 24 hours of incubation, the ethanol is removed and the balls are washed 4 times in PBS (PAA Laboratories, Cölbe). Ethanol and wash water are checked for DNA molecules by photometric absorption at 260 and 280 nm.
  • a primer is developed using the DNASTAR TM software and the reaction conditions of the primers (annealing temperature, MgCl 2 concentration, elongation time, etc.) are optimized.
  • a prepared and an unprepared sphere are heated in 200 ⁇ l TE to 95 ° C. and incubated on ice for 10 min.
  • a comparison is then made with a comparison with a dilution series of a known concentration of plasmid DNA to determine whether DNA can be determined on the spheres (see FIG. 4).
  • the bands are colored using ethidium bromide.
  • the content of pcDNA-IL-1 Ra in the spherical supernatant can be determined by comparing the band strengths of the PCR on the spherical supernatant with the band strengths of the known plasmid concentration.
  • the transfection takes place in a blood cell culture.
  • the glass spheres coated with DNA are introduced into a 48-well cell culture plate MTP (from Nunc, Wiesbaden) and incubated with 1 ml of heparinized whole blood at 37 ° C., 5% CO 2 . After 24 hours of incubation, the total protein content and the content of reporter or target protein in the serum supernatant are analyzed.
  • DNA polymerase (Taq polymerase) and dNTP 's are purchased and used by Qiagen (Hilden) in the "Supermix TM".
  • the primers are purchased from Invitrogen (Karlsruhe). Their concentrations are reduced to 20 ⁇ mol / l with distilled water set.
  • human serum is mixed 1: 1 with a dilution series of plasmid DNA.
  • the minimum plasmid concentration detected by PCR is 10 ng / ml (see FIG. 5).
  • a PCR sensitivity of 1 ⁇ g / ml can be determined by PCR on a dilution series of known plasmid concentration (see band 2 in FIG. 5).
  • a 1: 1 dilution series of plasmid DNA is added to the serum in order to detect the detection limit of the PCR.
  • the final detectable concentration of pcDNA-IL-1 Ra in human serum is 10 pg / ml (FIG. 6).
  • FIG. 7 shows the analysis of the human serum after the transfection by means of PCR. No DNA amounts of 10 pg / ml or more can be detected in the human serum after the transfection. This means that no DNA remains in the serum after transfection.
  • the target cells are incubated with the previously coated spheres for 24 h and then subjected to an IL-1 Ra and IL-1 ⁇ measurement.
  • the following serves as a control:
  • Sterile glass granules are used, for example granules from Roth (Karlsruhe), Order No. 17557.1, or granules of the following types:
  • Mohs hardness greater than or equal to 6
  • Hydrolytic I class 3 D Deeffoorrmmaattiioonnsstteemmppeerraattuurr ((°° CC)) :: 530 +/- 10
  • Transformation temperature (° C): 525
  • the surface of the granules is normally modified with the aid of a commercially available chromosulfuric acid preparation in a batch process, as set out in Example 1; however, any other acid and / or alkali listed in Example 1 can also be used.
  • the granules are then rinsed with water in order to wash away the acid / alkali residues.
  • the granules are then incubated at 121 ° C. under a pressure of 2 bar for at least 20 minutes in order to sterilize the granules and to saturate them with water.
  • the granules are then dried at 80 ° C. for 20 minutes.
  • the first washing steps are carried out in sterile 50 ml tubes. About 150 glass balls are then transferred to a plastic perfusor syringe, for example type No. 00137 (Becton, Dickinson and Company, Heidelberg), and coated with DNA in the syringe. The DNA solution is drained and the balls are washed. All further steps are carried out under the sterile bench. For sterilization, 70% ethanol is filled in, the syringe is closed and incubated for approx. 24 hours. This is followed by the washing steps with PBS (PAA Laboratories, Cölbe), with PBS being filled in at the top and allowed to run off again.
  • PBS PBS
  • syringe Adapted to the size of the syringe, approximately 1, 2, 4 or 10 cm 3 , or possibly more or less, of the prepared spheres are transferred to a second sterile syringe. If necessary, the syringe is filled in addition to the sterilized and modified granules with a sufficient amount of an anticoagulant such as heparin (Liquemin TM, heparin sodium TM 2500 IU) or Na citrate. This syringe is closed and sealed. b) general use of the syringe
  • the user removes the sterile cutlery from the packaging and takes blood from the patient.
  • the syringe has a septum at its opening in the closure attachment, which is pierced by the removal accessory, that is, the needle of the adapter, for removal. After removing the adapter, the septum closes again automatically. After taking blood, the syringe stamp is broken off at a predetermined breaking point.
  • FIG. 12 shows a preferred embodiment of this syringe.
  • the syringe with blood is then incubated for 24 hours at about 37 ° C to 41 ° C.
  • the incubation is carried out horizontally.
  • the blood can preferably be decanted and centrifuged. After centrifugation, the plasma is then removed through a sterile front filter, for example 0.2 ⁇ m.
  • Blood is drawn from a volunteer donor using the prepared syringe.
  • an ORTHOKIN ⁇ syringe from ORTHOGEN, Düsseldorf
  • a perfusor syringe without balls and a 10 ml serum tube (from Sarstedt, Nümbrecht) are taken as zero samples.
  • the zero sample is centrifuged immediately after taking off at 4000 xg at 4 ° C for 10 min and the serum supernatant is frozen and stored at -20 ° C.
  • the syringes are incubated at 37 ° C and 5% CO 2 for 24 hours. After incubation, the serum is removed and centrifuged at 4000 xg, 4 ° C, 10 min to remove all blood cells.
  • the supernatant is with a 20 ml syringe (Sarstedt, Nümbrecht) drawn up, sterile filtered with a 0.2 ⁇ m filter (Minisart TM, Sartorius) and filled into 1.8 ml tubes.
  • the serum is frozen at -20 ° C and stored for analysis.
  • the serum obtained is carefully analyzed.
  • a sterility test and a measurement of the transgene activity are carried out. It must be ensured that a normal quality control can be carried out and is not adversely affected.
  • a syringe as a withdrawal system permits clinical use.
  • the quality controls of the blood product that are common in transfusion medicine, such as screening for HCV, HBV, HIV and syphillis, give the same result in all tested systems.
  • the sterility test showed that no germs were found in all systems after the serum had been processed.
  • a density gradient solution is used to isolate PBMCs (mononuclear blood cells).
  • PBMCs nonuclear blood cells
  • uncoagulated whole blood is diluted in equal parts with culture medium or physiological saline (eg Dulbecco 's PBS).
  • 50 ml centrifuge tubes are provided with 12.5 ml separating solution (density 1.077 g / ml) and the diluted whole blood is carefully layered over the separating solution (up to approx. 25 ml per tube).
  • the tubes are centrifuged at 400 xg for 30 min at 15 to 25 ° C. After centrifugation, mononuclear cells form a white boundary layer between the plasma and the gradient solution. Erythrocytes and granulocytes are in the sediment, and in the serum there are thrombocytes.
  • PBMCs mononuclear cells
  • culture medium or a physiological salt solution Dulbecco 's PBS
  • the pellet is resuspended and the cells are washed 2 to 3 times with RPMI 1640 cell culture medium (with L-glutamine) (Invitrogen, Düsseldorf, Order No .: 21875034).
  • a cell suspension is exposed to one or more electrical pulses in the presence of a DNA solution. This creates pores in the cell membrane through which the DNA can enter the cell. The formation of the pores depends on various factors and the pores must be closed again after the electroporation. Temperature and electroporation medium are particularly important.
  • the DNA migrates into the nucleus and is transcribed in the nucleus. The migration to the core is supported electrophoretically with the help of the pulses. Different pulses are usually applied. The first or the first pulses are short and strong, that is to say they have a high field strength, the subsequent pulses are possibly weaker and can have different parameters (see below).
  • Cell number 10 4 to 10 10 cells per ml, preferably 10 7 cells per ml
  • Amount of DNA 1 to 100 ⁇ g per batch, preferably 20 ⁇ g per batch
  • Field strength 10 to 2500 V / cm, i.e. 4 to 1000V, with a 4mm cuvette: preferably 1500V / cm, i.e. 600 V
  • Pulse number 1 to 100, preferably 10
  • Pulse duration 1 to 1500 ⁇ sec, preferably 0.1 sec
  • Pulse interval 0.01 to 1 sec, preferably 1 sec
  • Electroporation medium RPMI
  • the PBMCs are incubated in media with growth-stimulating factors.
  • the cultivation takes place in RPMI 1640 at 37 ° C, 5% CO 2 and 10% autologous plasma, expediently with the addition of growth-stimulating substances such as 10-30 U / ml IL-2 (Röche, Mannheim) or 2-10 ⁇ g / ml PHA -M (Röche, Mannheim).
  • the composition of the medium is RPMI + 10% AP + 10 U / ml IL-2.
  • the electroporation takes place under the following conditions: 10 7 cells per ml, 20 ⁇ g DNA, 1500 V / cm in 4 mm cuvette, 10 pulses, 0.1 sec pulse duration, 1 sec pulse interval and subsequent incubation on ice for 15 min.
  • FIG. 10 shows the specific activity of the ⁇ -galactosidase after electroporation of PBMCs with pVaxLacZ. There is a significant increase in the specific activity of the ⁇ -galactosidase in samples electroporated with DNA compared to the controls that were not electroporated or electroporated without DNA.
  • the surface of the inner structure of the brand-new and originally packaged syringe and of the brand-new and originally packaged glass granulate is washed and modified in accordance with Example 1: the syringe is for this purpose completely and one-to-ten times, preferably three times, sprayed out and sprayed out with acid and / or Alkali treated and cleaned or modified. After the last draw up the syringe sealed at the bottom and incubated in the filled state for 5 to 30 min with the acid and / or alkali.
  • the syringe plunger is then removed and washed two to ten times, preferably four times, by completely filling and draining the syringe barrel with fresh ultrapure water, care being taken that the wash water is completely filled and filled.
  • the syringe plunger is then immersed in acid and / or alkali and washed off thoroughly with distilled water.
  • Pistons and syringes that are separated from one another, including any glass beads they may contain, are sealed in Melag film with an indicator field (Melag, Melafol 1502) (Melag, Melaseal).
  • the syringes packaged in this way are dried in a drying cabinet (Melag dry sterilizer) at 80 ° C for at least 60 min.
  • the dried packaged syringes are then autoclaved at 132 ° C. for 30 minutes at 2 bar (Wolf Autoclave HRM 242 II) and dried again at 80 ° C. for at least 60 minutes.
  • the granules are washed several times with saline / buffer and incubated in the plasmid saline for at least 2 hours.
  • This plasmid contains at least one sequence which codes for a protein and / or effector molecule, and at least one regulatory element such as a promoter which is active in eukaryotic cells, for example the pcDNA1-IL-1Ra.
  • the pyrogen-free nature of the DNA used is crucial for high protein and / or effector production.
  • the coated balls or Granules are washed after the incubation and sterilized with ethanol or gas in a manner known per se, preferably as shown in Example 1.
  • heparin e.g. Liquemin TM N 2500, Heparin-Sodium TM 2500 IU
  • citrate e.g. ACDA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Manufacturing & Machinery (AREA)

Abstract

L'invention concerne un procédé de fabrication de compositions sanguines induites, à partir de sang, les globules exprimant et sécretant éventuellement une ou plusieurs protéines et/ou molécules effectrices d'utilité thérapeutique et/ou diagnostique.
EP03727267A 2002-03-22 2003-03-21 Procede et agent de fabrication de compositions sanguines therapeutiquement actives Withdrawn EP1490112A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10213780A DE10213780A1 (de) 2002-03-22 2002-03-22 Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen
DE10213780 2002-03-22
PCT/EP2003/002969 WO2003080122A1 (fr) 2002-03-22 2003-03-21 Procede et agent de fabrication de compositions sanguines therapeutiquement actives

Publications (1)

Publication Number Publication Date
EP1490112A1 true EP1490112A1 (fr) 2004-12-29

Family

ID=28050919

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03727267A Withdrawn EP1490112A1 (fr) 2002-03-22 2003-03-21 Procede et agent de fabrication de compositions sanguines therapeutiquement actives

Country Status (5)

Country Link
EP (1) EP1490112A1 (fr)
JP (1) JP2005529857A (fr)
AU (1) AU2003233947A1 (fr)
DE (1) DE10213780A1 (fr)
WO (1) WO2003080122A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010237191A1 (en) 2009-04-07 2011-11-03 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
EP2475372B2 (fr) 2009-09-10 2020-10-21 Velin-Pharma A/S Procédé d'élaboration de micro-arn et application thérapeutique de celui-ci
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
WO2012076193A1 (fr) 2010-12-10 2012-06-14 Orthogen Ag Préparations combinées contenant des exosomes et un corticostéroïde
WO2012076194A1 (fr) 2010-12-10 2012-06-14 Orthogen Ag Préparations combinées contenant un antagoniste de la cytokine et un corticostéroïde

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020034495A1 (en) * 1989-06-14 2002-03-21 W. French Anderson Gene therapy
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU2001251132A1 (en) * 2000-03-31 2001-10-15 University Technology Corporation Expression of uncoupling protein (ucp) in plants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03080122A1 *

Also Published As

Publication number Publication date
WO2003080122A1 (fr) 2003-10-02
AU2003233947A1 (en) 2003-10-08
DE10213780A1 (de) 2003-11-27
JP2005529857A (ja) 2005-10-06

Similar Documents

Publication Publication Date Title
DE3027105C2 (fr)
DE3209127C2 (fr)
EP1151004B1 (fr) Procede de production d'antagonistes des recepteurs de l'interleukine 1, d'une proteine a activite therapeutique, a partir de fluides corporels
DE2535554C2 (de) Biologisches Verfahren
DE69229272T2 (de) Topischer fibrinogenkomplex
DE60012549T2 (de) Verfahren zur isolierung von nukleinsäuren und kit
DE3509202A1 (de) Verfahren zur induktion einer immunantwort durch immunisierung mit eingekapselten antigen erzeugenden zellen
DE19648625A1 (de) Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
DE3209098A1 (de) Verfahren zur kultivierung verankerungsabhaengiger zellen
WO2000024420A1 (fr) Procede de production d'un agent antiviral
DE69329340T2 (de) Aufbewahren von stammzellen
EP1490112A1 (fr) Procede et agent de fabrication de compositions sanguines therapeutiquement actives
WO2023088991A1 (fr) Procédé de concentration d'au moins une substance cible dans un échantillon liquide
DE602004003163T2 (de) Verfahren zur Bereitstellung von Proben zum Nachweis
DE68913602T2 (de) Gewebe-Immobilisierungs- und Zellkultursystem und Verfahren zum Anbringen biologisch wirksamer Teile an einem Substrat.
WO2022034355A1 (fr) Procédé d'extraction d'exosomes
EP0889053B1 (fr) Préparations à base de BK-RiV pour le traitement de maladies prolifératives cellulaires
EP1246631B1 (fr) Procede et dispositif pour augmenter et/ou reduire la concentration en substances a effet immunomodulateur dans des melanges de substances
RU2084523C1 (ru) Способ получения питательной среды для культивирования лимфоцитов крови человека
WO1996007904A1 (fr) Procede d'essai toxicologique de matieres, en particulier de matieres plastiques, et dispositif servant a la mise en ×uvre du procede
EP3561045B1 (fr) Procédé de culture et de différenciation de cellules
EP0899271B1 (fr) Procédé d'induction de protéines thérapeutiquement actives
DE4108464C1 (en) Nutrient medium for cell culture - contg. activated human blood plasma contg. increased amt. of albumin, reduced amt. of gamma globulin and cell growth inhibiting substances
DE10018681B4 (de) Therapeutisches Mittel für die autologe Immuntherapie von Tumoren sowie Verfahren zur Herstellung eines solchen Mittels
WO1996025485A1 (fr) Mise en culture in vitro de souches de trypanosomes pleomorphes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041022

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20050114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050525